Comprehensive Report: Daclizumab (DB00111) - A Case Study in Immunomodulation, Efficacy, and Unforeseen Risk

I. Executive Summary: The Rise and Fall of a Promising Immunomodulator

Daclizumab represents a compelling and cautionary chapter in the history of biopharmaceutical development. A humanized monoclonal antibody, it was engineered with a novel and highly specific mechanism of action targeting the interleukin-2 (IL-2) receptor pathway. Its trajectory spanned two decades and two distinct therapeutic indications, beginning with a successful tenure in transplant medicine as Zenapax and culminating in its reinvention as Zinbryta, a potent, once-monthly therapy for relapsing forms of multiple sclerosis (MS).[1]

The promise of Daclizumab for MS was underpinned by robust clinical trial data. The pivotal Phase IIb SELECT and Phase III DECIDE trials demonstrated remarkable efficacy, significantly reducing relapse rates, disability progression, and radiological disease activity. Notably, in the DECIDE trial, Daclizumab proved superior not only to placebo but also to a first-line active comparator, interferon beta-1a, establishing it as a powerful new option for patients with inadequate responses to other treatments.[1] This efficacy was directly linked to its unique immunomodulatory effect: a re-balancing of the immune system that involved both the suppression of pathogenic T-cells and the expansion of regulatory Natural Killer (NK) cells.[6]

However, this profound efficacy was inextricably linked to a catastrophic risk profile that emerged over time. Initial concerns centered on severe hepatotoxicity, including cases of autoimmune hepatitis and liver failure, which prompted a prominent Boxed Warning from the U.S. Food and Drug Administration (FDA) and the implementation of a stringent Risk Evaluation and Mitigation Strategy (REMS) program.[2] The final, decisive blow came after its launch, with post-marketing reports of rare but severe and often fatal inflammatory brain disorders, including encephalitis and meningoencephalitis.[11] These events revealed that the very mechanism that so effectively controlled MS in the central nervous system could also trigger devastating secondary autoimmune attacks on other tissues.

Faced with an evolving and unacceptable benefit-risk profile, the manufacturers Biogen and AbbVie voluntarily withdrew Daclizumab from the global market in March 2018.[15] The story of Daclizumab thus serves as a critical case study in modern drug development. It illustrates the profound challenge of balancing the therapeutic potential of novel immunotherapies against rare but severe risks that may only become fully apparent after widespread clinical use. It underscores the limitations of pre-market safety assessments for detecting low-frequency events and affirms the paramount importance of rigorous, continuous pharmacovigilance in protecting public health.

II. Molecular Profile and Pharmacological Characteristics of Daclizumab (DB00111)

Structure, Composition, and Formulation

Daclizumab is a biotechnology-derived drug, classified as a whole, humanized monoclonal antibody of the immunoglobulin G1 (IgG1) subtype.[1] It was developed by PDL BioPharma (then Protein Design Labs) through the humanization of a murine (mouse) monoclonal antibody known as anti-Tac.[1] This process was essential to minimize the potential for immunogenic reactions in human recipients. The final structure is a chimaera, composed of approximately 90% human and 10% murine protein sequences.[6] The human components were derived from the constant domains of human IgG1 and the variable framework regions of the human Eu myeloma antibody. The smaller murine portion consists of the complementarity-determining regions (CDRs)—the specific parts of the antibody that bind to the target—which were taken from the original anti-Tac antibody.[6]

Structurally, Daclizumab consists of two identical humanized gamma-1 heavy chains and two identical humanized kappa light chains, with a total molecular weight of approximately 144 kilodaltons (kDa).[6] It is produced using recombinant DNA technology in a mammalian cell line (NS0) within an animal component-free medium.[6]

For its use in multiple sclerosis under the trade name Zinbryta, Daclizumab was supplied as a sterile, preservative-free, colorless to slightly yellow, and clear to slightly opalescent solution for injection. It was available in a single-dose prefilled autoinjector or a single-dose prefilled syringe, each delivering 150 mg of the drug in a 1 mL volume.[6]

Table 1: Key Properties of Daclizumab (DB00111)

Characteristic	Value/Description	Source(s)
Drug Name	Daclizumab	1
DrugBank ID	DB00111	1
Type	Biotech, Whole Antibody	1
CAS Number	152923-56-3	1
Molecular Weight	Approx. 144 kDa	6
Source	Humanized (from murine mAb anti-Tac)	1
Antibody Subtype	Humanized IgG1	6
Target	IL-2 Receptor Alpha Subunit (CD25)	1
Formulation	150 mg/mL solution for injection	6
Trade Names	Zinbryta (MS), Zenapax (transplant, discontinued)	1

Pharmacokinetics: Absorption, Distribution, Metabolism, and Elimination (ADME)

The pharmacokinetic profile of Daclizumab was characterized by slow absorption, limited distribution, and a long elimination half-life, consistent with a large therapeutic protein.

Absorption: Following a single 150 mg subcutaneous (SC) injection, Daclizumab is slowly absorbed, reaching maximum serum concentrations (Tmax​) in approximately 5 to 7 days.[1] A cross-study analysis determined its absolute bioavailability to be high, at about 90%.[1]

Distribution: When administered as a once-monthly 150 mg SC injection, Daclizumab accumulates to a level approximately 2.5 times that of a single dose, achieving steady-state serum concentrations by the fourth dose (i.e., after approximately four months of treatment).[6] At steady state, the mean maximum concentration (

Cmax​) is approximately 30 µg/mL, and the mean minimum concentration (Cmin​) is approximately 15 µg/mL.[6] The steady-state volume of distribution (

Vd​) is approximately 6.34 L, indicating that the drug's distribution is largely confined to the vascular and interstitial fluid compartments, with limited penetration into deep tissues.[6]

Metabolism: As a large protein-based therapeutic, Daclizumab is not metabolized by the cytochrome P450 (CYP450) enzyme system in the liver.[1] Instead, it is presumed to be degraded through general protein catabolism, where proteases break it down into smaller peptides and constituent amino acids, which are then recycled by the body. This is the same pathway through which endogenous immunoglobulins are cleared.[1]

Elimination: Daclizumab exhibits slow clearance from the body, with a population pharmacokinetic analysis estimating the clearance rate at 0.212 L/day.[6] This slow clearance results in a long terminal elimination half-life of approximately 21 days, with a reported range of 11 to 38 days.[1] This long half-life provided the rationale for the convenient once-monthly dosing schedule. However, it also meant that the biological effects of the drug, and therefore the risk of adverse events, could persist for 8 to 12 weeks after the last dose was administered.[12] In patients who developed neutralizing antibodies against the drug, clearance was observed to be, on average, 19% higher.[6]

Table 2: Summary of Pharmacokinetic Parameters

Parameter	Value	Source(s)
Bioavailability (SC)	~90%	1
Time to Peak Concentration (Tmax​)	5-7 days	1
Elimination Half-life (t1/2​)	~21 days (range 11-38 days)	1
Volume of Distribution (Vd​)	~6.34 L	6
Clearance (CL)	~0.212 L/day	6
Time to Steady State	By the 4th monthly dose	1

III. A Dual-Edged Sword: The Complex Mechanism of Action of Daclizumab

The therapeutic efficacy and the eventual downfall of Daclizumab are both rooted in its unique and powerful modulation of the interleukin-2 (IL-2) signaling pathway. Its mechanism was not one of simple immunosuppression but rather a profound and specific re-balancing of distinct immune cell populations, which ultimately proved to be a double-edged sword.

The Interleukin-2 (IL-2) Signaling Axis

The IL-2 system is a cornerstone of the adaptive immune response, acting as a master regulator of lymphocyte activation, proliferation, survival, and differentiation.[2] The cellular response to IL-2 is dictated by the composition of the IL-2 receptor (IL-2R) on the cell surface. This receptor is assembled from up to three distinct protein chains:

• IL-2Rα (CD25): The alpha chain, which binds IL-2 with low affinity on its own.
• IL-2Rβ (CD122): The beta chain.
• Common gamma chain (γc, CD132): A chain shared by several other cytokine receptors.[7]

These chains combine to form three functionally distinct receptors:

1. Low-affinity IL-2R: Composed solely of the CD25 subunit.[7]
2. Intermediate-affinity IL-2R: A dimer of the CD122 and CD132 chains. This receptor is notably expressed on resting T-cells and, critically for Daclizumab's mechanism, on Natural Killer (NK) cells.[1]
3. High-affinity IL-2R: A heterotrimer composed of all three chains (CD25, CD122, and CD132). This receptor is transiently expressed at high levels on the surface of activated T-cells, which are key drivers of the autoimmune pathology in MS. It is also constitutively expressed on regulatory T-cells (Tregs), making them exquisitely sensitive to IL-2 and dependent on it for their survival and function.[2]

Daclizumab's Primary Action: Selective Blockade of the High-Affinity IL-2 Receptor

Daclizumab was designed to bind with high affinity to the CD25 subunit (also known as the Tac subunit) of the IL-2R.[1] By occupying this site, it physically prevents IL-2 from binding to and signaling through the high-affinity receptor complex.[7] This targeted blockade has several direct and profound consequences on the immune system:

• Inhibition of Activated T-cell Expansion: By blocking the high-affinity IL-2R, Daclizumab inhibits the IL-2-mediated survival signals and clonal expansion of recently activated pathogenic T-cells, thereby dampening the autoimmune attack on the central nervous system.[2]
• Inhibition of Regulatory T-cell (Treg) Function: Because Tregs rely on the high-affinity IL-2R for their maintenance and function, Daclizumab's blockade also leads to a reversible decrease in the number and activity of these crucial immunoregulatory cells.[21]
• Inhibition of Dendritic Cell Trans-presentation: The drug also interferes with the ability of mature dendritic cells to "trans-present" IL-2 to primed T-cells, providing another layer of inhibition on antigen-specific T-cell responses.[7]

The Unintended Consequence: Expansion of CD56bright Natural Killer (NK) Cells

The most innovative and ultimately pivotal aspect of Daclizumab's mechanism was an indirect effect of its primary action. Activated T-cells and Tregs are major consumers of IL-2 in the body. By blocking their ability to bind IL-2 via the high-affinity receptor, Daclizumab dramatically reduces the overall consumption of this cytokine.[20] This leads to a significant increase in the bioavailability of free IL-2 in the serum.[20]

This surplus IL-2 becomes available to signal through the intermediate-affinity IL-2R (CD122/CD132), which is not blocked by Daclizumab as it lacks the CD25 subunit.[1] A key cell population that expresses this intermediate-affinity receptor is the CD56bright subset of NK cells. These cells have immunoregulatory properties and are distinct from the more cytotoxic CD56dim NK cells. The increased IL-2 signal drives a dramatic expansion and activation of these CD56bright NK cells.[1] In fact, the therapeutic efficacy observed in MS clinical trials was found to directly correlate with the degree of this NK cell expansion.[23] These activated, immunoregulatory NK cells are believed to contribute to the therapeutic effect by gaining access to the intrathecal compartment and selectively eliminating autologous activated T-cells.[6]

This complex interplay reveals that Daclizumab's mechanism was far more nuanced than simple immunosuppression. It did not broadly weaken the immune system; rather, it initiated a powerful immunomodulatory shift, actively suppressing pathogenic T-cell responses while simultaneously amplifying a regulatory NK cell response. This re-balancing was the source of its impressive clinical efficacy. However, this same forceful manipulation of the immune system is also what likely created the conditions for the severe, organ-specific autoimmune toxicities that led to its withdrawal. By concurrently inhibiting Tregs—the immune system's primary "peacekeepers" responsible for maintaining self-tolerance—and activating cytotoxic NK cells, Daclizumab created a state of profound immune dysregulation. In susceptible individuals, this dysregulated state could manifest as a loss of tolerance and a new autoimmune attack on self-antigens in organs such as the liver and brain, explaining the emergence of autoimmune hepatitis and inflammatory encephalitis.[8] The drug's benefit and its risk were, therefore, two outcomes of the exact same powerful mechanism.

IV. Clinical Efficacy in Relapsing Multiple Sclerosis: Analysis of Pivotal Trials

The approval of Daclizumab for relapsing forms of multiple sclerosis was based on a robust clinical development program that demonstrated significant and superior efficacy in reducing disease activity. The key evidence came from two pivotal trials, SELECT and DECIDE, supported by long-term extension studies.

The SELECT Trial (Phase IIb, Placebo-Controlled - NCT00390221)

The SELECT trial was a 52-week, randomized, double-blind, placebo-controlled study designed to establish proof-of-concept and evaluate the efficacy and safety of Daclizumab High-Yield Process (HYP) in 600 patients with relapsing-remitting MS (RRMS).[4] Patients were randomized to receive subcutaneous Daclizumab HYP 150 mg, Daclizumab HYP 300 mg, or placebo once every 4 weeks.

The trial met its primary and key secondary endpoints, demonstrating a powerful effect on clinical and radiological measures of MS activity:

• Annualized Relapse Rate (ARR): The primary endpoint, ARR, was significantly reduced compared to placebo. The 150 mg dose group had an ARR of 0.21 and the 300 mg group had an ARR of 0.23, representing a 54% and 50% reduction, respectively, compared to the placebo group's ARR of 0.46 (p<0.001 for both).[4]
• Relapse-Free Patients: Consequently, a significantly greater proportion of patients treated with Daclizumab remained relapse-free over the 52-week period: 81% in the 150 mg group and 80% in the 300 mg group, versus only 64% in the placebo group (p<0.001).[4]
• Disability Progression: The 150 mg dose demonstrated a statistically significant 57% reduction in the risk of 3-month confirmed disability progression (p=0.021). The 300 mg dose showed a similar trend with a 43% risk reduction that did not reach statistical significance (p=0.091).[4]
• MRI Outcomes: Daclizumab showed a profound impact on MRI markers of inflammation. Compared to placebo, it significantly reduced the number of new or newly enlarging T2-hyperintense lesions by up to 79% and the number of new gadolinium-enhancing (Gd+) lesions by up to 78%.[4]
• Patient-Reported Outcomes: Treatment with the 150 mg dose also led to significant improvements in patient-reported health-related quality of life (HRQoL), as measured by both the physical and psychological impact scales of the Multiple Sclerosis Impact Scale (MSIS-29).[25]

Table 3: Key Efficacy Endpoints from the SELECT Trial (vs. Placebo at 52 Weeks)

Endpoint	Daclizumab 150mg	Daclizumab 300mg	Placebo	p-value (vs. Placebo)	Source(s)
Annualized Relapse Rate (ARR)	0.21	0.23	0.46	<0.001	4
Proportion Relapse-Free	81%	80%	64%	<0.001	4
Risk Reduction in 3-Month Sustained Disability Progression	57%	43%	N/A	p=0.021	4
Reduction in New/Newly Enlarging T2 Lesions	70%	79%	N/A	<0.001	27
Reduction in New Gd+ Lesions	69%	78%	N/A	<0.001	27

The DECIDE Trial (Phase III, Active-Comparator - NCT01064401)

Following the success of SELECT, the DECIDE trial was launched. It was the largest and longest head-to-head study in MS at the time, designed to demonstrate the superiority of Daclizumab over an established first-line therapy.[3] This two- to three-year, randomized, double-blind study compared the efficacy and safety of Daclizumab HYP 150 mg SC monthly (n=919) against intramuscular interferon beta-1a (Avonex) 30 mcg weekly (n=922) in patients with RRMS.[3]

The results of DECIDE were pivotal, establishing Daclizumab's superior efficacy:

• Annualized Relapse Rate (ARR): Daclizumab significantly reduced the ARR by 45% compared to interferon beta-1a (p<0.001), meeting the study's primary endpoint.[1]
• MRI Outcomes: Daclizumab was also superior in reducing radiological disease activity, showing a 54% reduction in the number of new or newly enlarging T2-hyperintense lesions at 96 weeks compared to interferon beta-1a (p<0.001).[3]
• No Evidence of Disease Activity (NEDA): A key composite measure of holistic disease control (defined as no relapses, no confirmed disability progression, and no new MRI lesions), NEDA was achieved by significantly more patients on Daclizumab. Over 96 weeks, 24.6% of Daclizumab-treated patients achieved NEDA status compared to only 14.2% of patients on interferon beta-1a (p<0.0001).[28]
• Patient-Reported Outcomes: Daclizumab treatment resulted in net improvements on the physical impact subscale of the MSIS-29 and reduced the risk of clinically meaningful worsening compared to interferon beta-1a.[28]

Long-Term Extension Studies (SELECTION, SELECTED, EXTEND)

Patients who completed the pivotal trials were eligible to enroll in long-term open-label extension studies, such as SELECTION (NCT00870740) and EXTEND (NCT01797965), which provided data for up to eight years of continuous treatment.[5] These studies confirmed that the robust clinical and radiological efficacy of Daclizumab was sustained over the long term.[5] However, this extended observation period was also critical in revealing the cumulative and evolving safety risks, including a fatal case of autoimmune hepatitis in the SELECTION trial, which foreshadowed the severe adverse events that would ultimately lead to the drug's withdrawal.[28]

Table 4: Key Efficacy Endpoints from the DECIDE Trial (Daclizumab vs. Interferon Beta-1a)

Endpoint	Daclizumab 150mg	Interferon beta-1a	Relative Reduction / Odds Ratio	p-value	Source(s)
Reduction in ARR	N/A	N/A	45% reduction	<0.001	5
Reduction in New/Newly Enlarging T2 Lesions (at 96 weeks)	N/A	N/A	54% reduction	<0.001	5
Proportion Achieving NEDA (at 96 weeks)	24.6%	14.2%	OR: 2.059	<0.0001	30

V. The Unraveling Safety Profile: From Hepatotoxicity to Neuroinflammation

Despite its demonstrated efficacy, the clinical use of Daclizumab was ultimately terminated due to an unacceptable safety profile characterized by severe and unpredictable immune-mediated adverse reactions affecting multiple organ systems.

Common and Class-Related Adverse Events

In clinical trials, the most common adverse reactions reported more frequently with Daclizumab than with the active comparator (interferon beta-1a) included nasopharyngitis, upper respiratory tract infection, rash, influenza, dermatitis, eczema, oropharyngeal pain, bronchitis, and lymphadenopathy.[8]

• Infections: Infections were common, and the incidence of serious infections was higher in the Daclizumab group compared to the interferon beta-1a group in the DECIDE trial (4% vs. 2%).[8] This risk necessitated screening for latent tuberculosis prior to initiating therapy.[8]
• Cutaneous Reactions: Skin-related adverse events were very frequent, including rash, dermatitis, and eczema.[8] In the DECIDE trial, serious cutaneous reactions occurred in 2% of Daclizumab-treated patients, compared to less than 1% in the interferon group.[28]

The First Major Signal: Severe Hepatic Injury and Autoimmune Hepatitis

The most significant safety concern identified during the clinical development program was the risk of severe, and potentially fatal, liver injury.[2]

• Incidence and Severity: Daclizumab was found to cause serious drug-induced liver injury (DILI), including cases of liver failure and autoimmune hepatitis. In the clinical trial program, elevations in serum aminotransferases (ALT or AST) greater than five times the upper limit of normal (>5x ULN) occurred in 4-6% of patients treated with Daclizumab, compared to 3% for interferon beta-1a.[2] Serious DILI was reported in 0.9% of all Daclizumab-treated subjects.[10]
• Fatalities: The risk was underscored by fatal outcomes. One death from autoimmune hepatitis occurred in a patient in the SELECTION extension study, and another patient died from complications following a severe cutaneous reaction, both considered likely related to Daclizumab use.[10]
• Regulatory Response: This clear signal of hepatotoxicity led the FDA to include a Boxed Warning on the U.S. product label. The drug was contraindicated in patients with pre-existing hepatic disease or impairment.[2] Furthermore, its approval was contingent on a stringent Risk Evaluation and Mitigation Strategy (REMS) program, which mandated monthly monitoring of liver function tests for all patients before each dose, during treatment, and for up to six months after discontinuation.[3]

The Final Straw: Severe Inflammatory Brain Disorders

The adverse event that ultimately sealed Daclizumab's fate emerged during post-marketing surveillance. In early 2018, a cluster of cases of severe inflammatory brain disorders was reported in patients treated with the drug, leading to its rapid withdrawal from the market.[11]

• Clinical Presentation: Reports described patients developing severe encephalitis and meningoencephalitis.[13] These cases were clinically distinct from MS relapses and were often accompanied by systemic symptoms such as fever, rash, gastrointestinal issues, and eosinophilia (an increase in eosinophil white blood cells).[14]
• Global Incidence: The initial reports included seven cases in Germany and one in Spain.[12] This number soon grew to 12 cases worldwide, of which at least three were fatal.[13]
• Specific Autoimmune Syndromes: Further investigation revealed that these neuroinflammatory events were manifestations of specific, severe secondary autoimmune syndromes triggered by Daclizumab:
• Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A majority of the German cases (6 of 7) met the diagnostic criteria for DRESS, a life-threatening, multi-organ hypersensitivity reaction characterized by rash, fever, eosinophilia, and internal organ involvement.[14]
• GFAPα IgG-Associated Encephalitis: At least one patient was diagnosed with this rare and specific form of autoimmune encephalitis, where the body produces antibodies against glial fibrillary acidic protein (GFAP), a protein in astrocytes in the brain. The condition was causally linked to Daclizumab treatment.[23]
• Prognosis and Timing: These conditions were often severe, required intensive care, showed poor response to standard immunosuppressive treatments, and resulted in high levels of disability or death.[14] Critically, these events could occur not only during active treatment but also for several months after the drug had been discontinued, complicating risk management.[22]

Table 5: Incidence of Key Adverse Events from Pivotal Clinical Trials

Adverse Event	Daclizumab 150mg (%)	Interferon beta-1a (%)	Placebo (%)	Source(s)
Serious Infections	4% (DECIDE)	2% (DECIDE)	0% (SELECT)	27
Serious Cutaneous Reactions	2% (DECIDE)	<1% (DECIDE)	0% (SELECT)	27
ALT/AST Elevations >5x ULN	6% (DECIDE)	3% (DECIDE)	<1% (SELECT)	27
Lymphadenopathy	5%	N/A	N/A	8
Depression/Depressed Mood	10%	N/A	N/A	10

Note: Data from different trials (DECIDE vs. interferon; SELECT vs. placebo) are presented for context. Direct comparison across trials is not intended.

VI. Regulatory Trajectory and Market Withdrawal: A Case Study in Pharmacovigilance

The regulatory history of Daclizumab is unique, marked by two distinct market approvals for different indications nearly two decades apart, followed by a rapid and decisive global withdrawal driven by post-marketing safety signals.

A Tale of Two Approvals

First Life (Zenapax): Daclizumab first entered the market under the brand name Zenapax, manufactured by Hoffmann-La Roche. It received FDA approval in December 1997 for the prophylaxis of acute organ rejection in patients receiving kidney transplants, making it the first humanized monoclonal antibody to be approved anywhere in the world.[1] It was used as part of an immunosuppressive regimen alongside cyclosporine and corticosteroids.[1] In 2009, Zenapax was withdrawn from the market. This decision was based on commercial factors—namely, the availability of newer and better therapeutic options for transplant patients—and was not driven by safety or efficacy concerns at that time.[1]

Second Life (Zinbryta): The drug was repurposed for neurology, leading to its second approval for multiple sclerosis.

• FDA Approval: On May 27, 2016, the FDA approved Daclizumab under the brand name Zinbryta for the treatment of adult patients with relapsing forms of MS.[1] Recognizing the significant risk of liver injury identified in clinical trials, the approval was granted with a restricted indication. Its use was "generally to be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS".[3] The approval was accompanied by a Boxed Warning for hepatic injury and the mandate for a comprehensive REMS program to ensure regular safety monitoring.[3]
• EMA Approval: The European Medicines Agency (EMA) also granted marketing authorization for Zinbryta in 2016 for relapsing forms of MS.[11] While initially approved with fewer restrictions, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) conducted a review in 2017 in response to post-marketing reports of liver failure. This led to a restriction of its use to align more closely with the FDA's second-line indication.[1]

Post-Marketing Actions and the March 2018 Voluntary Worldwide Withdrawal

The period following its launch was marked by escalating safety concerns. The 2017 EMA review highlighted that unpredictable and potentially fatal immune-mediated liver injury could occur during treatment and for up to 6 months after discontinuation.[13]

The situation reached a critical point in early 2018 with the emergence of reports of fatal inflammatory brain disorders. On March 2, 2018, the manufacturers, Biogen and AbbVie, took the decisive step of announcing a voluntary worldwide withdrawal of Zinbryta from the market.[11] The companies stated that given the "nature and complexity of adverse events being reported, characterizing the evolving benefit/risk profile of ZINBRYTA will not be possible going forward given the limited number of patients being treated".[12]

Regulatory agencies acted swiftly. The EMA and FDA issued immediate safety alerts and initiated a recall, recommending that no new patients start the therapy and that all current patients be transitioned to alternative treatments in close consultation with their neurologists.[11] All ongoing clinical trials involving Daclizumab were also terminated.[13]

Table 6: Timeline of Key Regulatory and Safety Events for Daclizumab

Date	Event	Significance/Details	Source(s)
Dec 1997	FDA approves Zenapax	First humanized mAb approved worldwide; for preventing kidney transplant rejection.	1
2009	Zenapax discontinued	Withdrawn from market due to commercial factors, not safety.	1
May 27, 2016	FDA approves Zinbryta	For relapsing MS, with a restricted indication, Boxed Warning for liver injury, and a mandatory REMS program.	1
July 2016	EMA approves Zinbryta	For relapsing forms of MS in the European Union.	11
Oct 2017	EMA restricts Zinbryta use	PRAC review of liver safety leads to restricted indication for patients who failed other therapies.	11
Mar 2, 2018	Voluntary Worldwide Withdrawal	Biogen and AbbVie announce withdrawal due to reports of serious inflammatory brain disorders.	11
Mar 2018	EMA/FDA issue safety alerts	Agencies recommend immediate suspension and recall; patients to be transitioned to other therapies.	11

VII. Comprehensive Review of Drug Interactions and Contraindications

The safety profile of Daclizumab necessitated specific contraindications and a range of warnings regarding its use and potential interactions with other medications.

Contraindications

The use of Daclizumab was strictly contraindicated in certain patient populations due to unacceptable risks:

• Pre-existing Hepatic Disease or Impairment: This was the most significant contraindication, stemming from the known risk of severe hepatotoxicity. It applied to patients with any pre-existing liver disease or those with baseline serum transaminase (ALT or AST) levels at least two times the upper limit of normal.[8]
• History of Hypersensitivity: Patients with a known history of a serious hypersensitivity reaction, such as anaphylaxis or angioedema, to Daclizumab or any of its excipients were not to be treated with the drug.[1]

Warnings and Precautions

Beyond the Boxed Warning for hepatic injury, the product labeling included several other critical warnings:

• Other Immune-Mediated Disorders: Prescribers were warned of the risk of a variety of other immune-mediated disorders affecting different organ systems, including skin reactions, lymphadenopathy (enlarged lymph nodes), and non-infectious colitis. These conditions could be serious and might require treatment with systemic corticosteroids.[8]
• Infections: Daclizumab treatment was associated with an increased risk of infections. It was recommended that treatment be withheld if a patient developed a serious infection until it resolved. Initiation of Daclizumab was to be avoided in patients with severe active infections, including tuberculosis.[8]
• Depression and Suicidality: Depression, depressed mood, and suicidal ideation were identified as potentially severe adverse events during clinical trials, requiring careful monitoring of patients' mental health status.[2]

Significant Drug-Drug Interactions

The immunomodulatory nature of Daclizumab created the potential for significant interactions:

• Concurrent Immunosuppressants/Immunomodulators: The risk and severity of adverse effects, particularly infections and immune dysregulation, could be increased when Daclizumab was combined with other agents that affect the immune system. Examples include alemtuzumab, anakinra, and apremilast.[17] Co-administration with such agents was generally to be avoided.
• Live Vaccines: As with other immunomodulatory therapies, the use of live attenuated vaccines (e.g., Bacillus Calmette-Guerin, measles, mumps, rubella) was not recommended during treatment. The suppressed T-cell response could increase the risk of developing a disseminated infection from the vaccine virus or bacterium itself.[17]
• Allogeneic Processed Thymus Tissue: The therapeutic efficacy of this specific treatment, which is designed to help reconstitute the immune system, could be diminished by Daclizumab's interference with T-cell function and development.[17]

VIII. Concluding Analysis: Lessons from the Daclizumab Experience

The story of Daclizumab is a powerful illustration of the promise and peril of developing highly targeted, novel immunotherapies. Its rise and fall offer critical lessons for clinical medicine, regulatory science, and the pharmaceutical industry, highlighting the intricate relationship between efficacy, mechanism, and safety.

The Efficacy-Toxicity Paradox: The central lesson from Daclizumab is that its profound therapeutic efficacy and its catastrophic toxicity were two sides of the same coin, both stemming directly from its unique mechanism of action. By specifically blocking the high-affinity IL-2 receptor, it achieved a potent and desirable immunomodulatory re-balancing: suppressing pathogenic T-cells while expanding regulatory NK cells. This mechanism delivered superior clinical and radiological outcomes compared to existing therapies. However, this same forceful manipulation—particularly the concurrent depletion of regulatory T-cells—disrupted the delicate state of immune tolerance. This created a permissive environment for the development of new, severe autoimmune attacks on other organs, manifesting as fatal hepatitis and encephalitis. The experience demonstrates that even highly specific and targeted interference with a central immune pathway can have unforeseen and devastating systemic consequences.

A Landmark Case for Pharmacovigilance: The Daclizumab saga is a textbook case for the indispensable role of post-marketing pharmacovigilance. The pre-market clinical trial program, which included over 2,200 patients, was sufficiently powered to detect the relatively common risk of liver injury.[10] However, it was statistically incapable of detecting the rare but fatal neuroinflammatory events, which occurred at a frequency of approximately 12 cases among the 8,000 patients treated worldwide post-approval.[11] This starkly illustrates that the true safety profile of a new drug, especially one with a novel mechanism, can only be fully characterized once it is used in a larger, more heterogeneous real-world population. The rapid detection of these events and the subsequent swift withdrawal of the drug underscore the life-saving importance of a robust and responsive global pharmacovigilance system.

Implications for MS Treatment and Drug Development: The withdrawal of such a highly effective agent left a significant therapeutic gap for patients with aggressive MS who had failed multiple other treatments. For the field of drug development, the Daclizumab experience has raised the bar for the safety evaluation of future immunomodulatory drugs. It highlights the urgent need for better preclinical models and predictive biomarkers that can identify individuals at high risk for developing severe immune-mediated adverse reactions. The focus must shift from merely assessing if a drug "works" to understanding the full spectrum of its immunological consequences.

The Lingering Scientific Value: Despite its ultimate clinical failure, the development and study of Daclizumab were not without value. The investigation into its mechanism provided invaluable and lasting insights into the complex immunology of multiple sclerosis. It particularly illuminated the previously underappreciated role of the innate immune system—specifically the CD56bright NK cell population—in regulating CNS autoimmunity.[7] While Daclizumab itself is no longer a therapeutic option, the knowledge gained from its journey continues to inform new research and has opened novel avenues for the development of future therapies that may be able to harness its benefits without repeating its tragic risks.

Works cited

1. Daclizumab - Wikipedia, accessed August 13, 2025, https://en.wikipedia.org/wiki/Daclizumab
2. Daclizumab - LiverTox - NCBI Bookshelf, accessed August 13, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548018/
3. Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (daclizumab) for Multiple Sclerosis - May 27, 2016, accessed August 13, 2025, https://news.abbvie.com/2016-05-27-Biogen-and-AbbVie-Receive-FDA-Approval-of-Once-Monthly-ZINBRYTA-daclizumab-for-Multiple-Sclerosis
4. A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Daclizumab HYP Monotherapy in Relapsing-Remitting Multiple Sclerosis: Primary Results of the SELECT Trial (S01.005) - Neurology.org, accessed August 13, 2025, https://www.neurology.org/doi/10.1212/WNL.78.1_supplement.S01.005
5. Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND), accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7934044/
6. AusPAR Attachment 1: Product Information for Daclizumab, accessed August 13, 2025, https://www.tga.gov.au/sites/default/files/auspar-daclizumab-170504-pi.pdf
7. Daclizumab Therapy for Multiple Sclerosis - ScienceDirect - DOI, accessed August 13, 2025, https://doi.org/10.1007/s13311-012-0147-4
8. ZINBRYTA (daclizumab) injection, for ... - accessdata.fda.gov, accessed August 13, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761029s007lbl.pdf
9. Daclizumab: MS Drug Uses, Side Effects & Interactions - MedicineNet, accessed August 13, 2025, https://www.medicinenet.com/daclizumab/article.htm
10. 761029Orig1s000 - accessdata.fda.gov, accessed August 13, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761029Orig1s000MedR.pdf
11. Management of MS Patients Treated With Daclizumab – a Case Series of 267 Patients - PMC, accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7506133/
12. Zinbryta® Withdrawn from Marketplace | MSAA - Multiple Sclerosis Association of America, accessed August 13, 2025, https://mymsaa.org/news/zinbryta-withdrawn
13. MS drug is suspended after reports of inflammatory brain disorders | The BMJ, accessed August 13, 2025, https://www.bmj.com/content/360/bmj.k1114
14. Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis - PubMed, accessed August 13, 2025, https://pubmed.ncbi.nlm.nih.gov/30657420/
15. FDA working with manufacturers to withdraw Zinbryta from the market in the United States, accessed August 13, 2025, https://www.fda.gov/drugs/drug-safety-and-availability/fda-working-manufacturers-withdraw-zinbryta-market-united-states
16. Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis, accessed August 13, 2025, https://investors.biogen.com/news-releases/news-release-details/biogen-and-abbvie-announce-voluntary-worldwide-withdrawal
17. Daclizumab: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 13, 2025, https://go.drugbank.com/drugs/DB00111
18. Daclizumab Biosimilar – Anti-IL2RA mAb – Research Grade - ProteoGenix, accessed August 13, 2025, https://us.proteogenix.science/product/daclizumab-biosimilar-anti-il2ra-mab-research-grade/
19. Daclizumab (Zinbryta®): An Emerging Therapy for the Treatment of Relapsing-Remitting Multiple Sclerosis - DigitalCommons@ONU, accessed August 13, 2025, https://digitalcommons.onu.edu/cgi/viewcontent.cgi?article=1186&context=paw_review
20. (PDF) Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis - ResearchGate, accessed August 13, 2025, https://www.researchgate.net/publication/331676831_Daclizumab_Mechanisms_of_Action_Therapeutic_Efficacy_Adverse_Events_and_Its_Uncovering_the_Potential_Role_of_Innate_Immune_System_Recruitment_as_a_Treatment_Strategy_for_Relapsing_Multiple_Sclerosis
21. Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse ..., accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6480729/
22. Daclizumab-induced encephalitis in multiple sclerosis Editorial - UCL Discovery, accessed August 13, 2025, https://discovery.ucl.ac.uk/id/eprint/10084082/1/BIANCHI%20-%20Daclizumab-induced%20encephalitis%20in%20multiple%20sclerosis%20%28manuscript%29.pdf
23. Daclizumab: Mechanisms of action, therapeutic efficacy, adverse events and its uncovering the potential role of innate immune system recruitment as a treatment strategy for relapsing multiple sclerosis - Providence, accessed August 13, 2025, https://providence.elsevierpure.com/en/publications/daclizumab-mechanisms-of-action-therapeutic-efficacy-adverse-even
24. GFAPα IgG-associated encephalitis upon daclizumab treatment of MS - Neurology.org, accessed August 13, 2025, https://www.neurology.org/doi/10.1212/NXI.0000000000000481
25. Daclizumab High-Yield Process Treatment Reduced the Impact of ..., accessed August 13, 2025, https://www.neurology.org/doi/10.1212/WNL.80.7_supplement.P03.212
26. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial | Request PDF - ResearchGate, accessed August 13, 2025, https://www.researchgate.net/publication/303137488_Daclizumab_high-yield_process_in_relapsing-remitting_multiple_sclerosis_SELECT_a_randomised_double-blind_placebo-controlled_trial
27. Biogen Idec and Abbott Present Positive Data for Daclizumab HYP from Select Phase 2B Trial at ECTRIMS/ACTRIMS, accessed August 13, 2025, https://investors.biogen.com/news-releases/news-release-details/biogen-idec-and-abbott-present-positive-data-daclizumab-hyp
28. Results from ZINBRYTA™ (Daclizumab High-Yield Process) Phase ..., accessed August 13, 2025, https://investors.biogen.com/news-releases/news-release-details/results-zinbrytatm-daclizumab-high-yield-process-phase-3-decide
29. Treatment with Daclizumab HYP Improved Disease-Specific Patient-Reported Outcomes Versus Interferon Beta-1a in Multiple Sclerosis in the Phase 3 DECIDE Trial (P7.209) - Neurology.org, accessed August 13, 2025, https://www.neurology.org/doi/10.1212/WNL.84.14_supplement.P7.209
30. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. - Neurology | Weill Cornell Medicine, accessed August 13, 2025, https://neurology.weill.cornell.edu/publications/no-evidence-disease-activity-patients-receiving-daclizumab-versus-intramuscular
31. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study., accessed August 13, 2025, https://mscenter.weillcornell.org/no-evidence-disease-activity-patients-receiving-daclizumab-versus-intramuscular-interferon-beta-1a
32. Relapsing Remitting Multiple Sclerosis (RRMS) Completed Phase 2 Trials for Daclizumab (DB00111) | DrugBank Online, accessed August 13, 2025, https://go.drugbank.com/indications/DBCOND0036413/clinical_trials/DB00111?phase=2&status=completed
33. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial - PubMed, accessed August 13, 2025, https://pubmed.ncbi.nlm.nih.gov/24656609/
34. Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis | ClinicalTrials.gov, accessed August 13, 2025, https://clinicaltrials.gov/study/NCT00870740?term=205ms201&rank=1&checkSpell=
35. The SELECT and DECIDE studies and their extension studies.41,42,51–53129 - ResearchGate, accessed August 13, 2025, https://www.researchgate.net/figure/The-SELECT-and-DECIDE-studies-and-their-extension-studies41-42-51-53-129_fig1_308044811
36. Daclizumab withdrawn from NHS after safety concerns - MS Society, accessed August 13, 2025, https://www.mssociety.org.uk/research/news/daclizumab-withdrawn-nhs-after-safety-concerns
37. What's happening in Neurology® Neuroimmunology & Neuroinflammation, accessed August 13, 2025, https://www.neurology.org/doi/10.1212/WNL.0000000000006993
38. Zinbryta (daclizumab) FDA Approval History - Drugs.com, accessed August 13, 2025, https://www.drugs.com/history/zinbryta.html
39. Daclizumab withdrawn from the market worldwide | Drug and Therapeutics Bulletin, accessed August 13, 2025, https://dtb.bmj.com/content/56/4/38.1
40. FDA Helping with Zinbryta® Withdrawal | MSAA - Multiple Sclerosis Association of America, accessed August 13, 2025, https://mymsaa.org/news/fda-helping-with-zinbryta-withdrawal/